As one the world's oldest biotechnology exhibition, BioJapan aims to accelerate and industrialize R&D in the field of regenerative medicine and provides fusion of digital technology to life science. Special focus is paid to provide new value by business partnering of industry, academia, and government all around the globe.
Accessing Global Markets and Regulators from Japan’s Innovative Biopharma Sector
Valuations of Tokyo Stock Exchange-listed biotechnology companies are reflective of intellectual property and commercialization strategy & performance. Approval from U.S. F.D.A. and getting global market access will strengthen the competence, which requires resources and know-how on successful clinical development strategy enablement. For start-ups and biotech companies, developing assets that draws potential acquisitive interests from global pharmaceutical companies is an alternative to commercial success. Thus, enough funding, competence in global clinical development are critical elements.
The strategic partnership between Fortrea and Beyond Next Ventures Inc. will further enhance the capabilities to support international expansion of Japan startups in global bio-pharmaceutical sector. While tremendous value including but not limited to actual funding that mature venture capital brings to key players, Fortrea as global CRO adds significant value by addressing the challenges Japan pharmaceutical industry is facing, further elevate competence in managing the complexity in clinical design, planning and execution.
The joint effort will build bridge between local and global market, thus benefit not only individual local biotech company but also global pharmaceutical ecosystem.
